Novo Nordisk is contesting Sen. Bernie Sanders' calls to reduce the list prices of Ozempic and Wegovy in the U.S., Bloomberg reports. In late April, the Senate Health, Education, Labor, and ...
Novo Nordisk reported great first quarter results again but free cash flow declined - in part due to high capital expenditures. At this point, we can expect the obesity market to continue growing ...
The diabetes drug Ozempic has been a hit for manufacturer Novo Nordisk. But its meteoric rise in popularity brings with it concerns for the patent holder due to emerging reports of patient harm and ...
Novo Nordisk, the maker of anti-diabetes and weight-loss drugs Ozempic and Wegovy, today displayed again why it has become Europe's biggest company by stock market value during the last year.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.
Novo Nordisk's already strong financials could look even better in the future as the company's drugs have loads of potential. The company's high-profit margins make it likely that earnings will ...
In the Man Markets Meeting this week, the great Rory Powe – soon to celebrate a decade at Man Group - spoke eloquently about Novo Nordisk, a firm whose GLP-1 semaglutide treatments for diabetes ...
Novo Nordisk cuts price of weight loss drug Wegovy as competition heats up on facebook (opens in a new window) Novo Nordisk cuts price of weight loss drug Wegovy as competition heats up on ...
Novo Nordisk (NVO) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.